A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection
Kidney360 · 2026-08 · 7 (8) · 1792-1806
DOI: 10.34067/kid.0000001208 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Kidney360, online erschienen am 14.05.2026. Verfasst von Beatrice P Concepcion und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Chicago, Chicago, Illinois. Hauptthemen laut MEDLINE: Graft Rejection, High-Throughput Nucleotide Sequencing, Kidney Transplantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Verici Dx.
Abstract (Originalsprache)
Key Points Pretransplant early acute rejection risk stratification offers a novel approach to personalized immunosuppression management in patients who received a kidney transplant. Stratifying immunologic risk independent of donor characteristics may help guide immunosuppression management in patients who received a kidney transplant. The pretransplant risk assessment gene set reflects metabolic and immune pathways involved in T-cell– and antibody-mediated mechanisms of transplant rejection.
Background
Although donor and recipient characteristics are used to estimate graft failure risk, they remain limited in predicting early acute rejection (EAR). We developed and validated a next-generation sequencing assay targeting the pretransplant immunologic profile to predict EAR following kidney transplantation.
Methods
This prospective, international study enrolled 321 kidney transplant participants across 13 sites, forming discovery and validation cohorts. Peripheral blood was collected before transplant and at 1, 3, 6, 12, and 24 months post-transplant, with protocol biopsies performed at 3 and 12 months, as well as any indication biopsies. Biopsies were assessed by a blinded central pathologist according to the 2019 Banff criteria. The pretransplant risk assessment (PTRA) test to evaluate RNA expression of a 29-gene signature algorithm designed to predict EAR risk was clinically validated using 122 deceased donor kidney transplant recipients.
Results
PTRA classified 31 of 122 participants (25%) as high risk and 91 (75%) as low risk. There were nine EAR events in the first 60 days post-transplant: 6/31 (19%) in the high-risk group and 3/91 (3%) in the low-risk group. PTRA discrimination for EAR at 60 days post-transplant yielded an area under the curve of 0.78 (95% confidence interval [CI], 64.4 to 91.5), P < 0.001. A cutoff of ≤45 was defined as low risk and >45 as high risk for EAR within 60 days post-transplant. Sensitivity was 0.67 (95% CI, 0.36 to 0.97), specificity 0.78 (95% CI, 0.70 to 0.86), positive predictive value 0.19 (95% CI, 0.05 to 0.33), and negative predictive value 0.97 (95% CI, 0.93 to 1.00). The odds ratio comparing patients identified as high versus low risk by PTRA was 7.04 (95% CI, 1.64 to 30.2), P = 0.009.
Conclusions
This study validates the ability of PTRA to stratify kidney transplant recipients as high or low risk for EAR using a pretransplant transcriptomic profile, with implications for graft health and personalized treatment management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Chicago, Chicago, Illinois.
- Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- Henry Ford Health System, Detroit, Michigan.
- Department of Internal Medicine, Northwestern University, Evanston, Illinois.
- Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- CHU Grenoble Alpes, Grenoble, France.
ORCID-Profile: Beatrice P Concepcion, Oriol Bestard, Milagros Samaniego-Picota, Rohini Prashar, M Javeed Ansari, Giorgia Comai, Elisa Gessaroli, Lionel Rostaing, Federico Alberici, Roslyn B Mannon, Joshua Augustine, Alvin Wee, Emilio Poggio, Pierpaolo DiCocco, Nicholae Leca, Saed Shawar, Chandra Bhati, David M Rothstein, Aravind Cherukuri, Anthony Chang, Fadi Salem, Michael W Kattan, Jesse D Schold, Patricia Connolly, Nehal Doshi, Lorenzo Gallon
Förderung
- Verici Dx
Zitieren
APA
Concepcion, B. P., Bestard, O., Samaniego-Picota, M., Prashar, R., Ansari, M. J., Comai, G., Gessaroli, E., Rostaing, L., Alberici, F., Mannon, R. B., Augustine, J., Wee, A., Poggio, E., DiCocco, P., Leca, N., Shawar, S., Bhati, C., Maluf, D., Rothstein, D. M., …, & Donovan, M. J. (2026). A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection. Kidney360, 7(8), 1792-1806. https://doi.org/10.34067/kid.0000001208
Vancouver
Concepcion BP, Bestard O, Samaniego-Picota M, Prashar R, Ansari MJ, Comai G, et al. A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection. Kidney360. 2026;7(8):1792-1806. doi:10.34067/kid.0000001208
BibTeX
@article{Concepcion2026,
author = {Concepcion, Beatrice P and Bestard, Oriol and Samaniego-Picota, Milagros and Prashar, Rohini and Ansari, M Javeed and Comai, Giorgia and Gessaroli, Elisa and Rostaing, Lionel and Alberici, Federico and Mannon, Roslyn B and Augustine, Joshua and Wee, Alvin and Poggio, Emilio and DiCocco, Pierpaolo and Leca, Nicholae and Shawar, Saed and Bhati, Chandra and Maluf, Daniel and Rothstein, David M and Cherukuri, Aravind and Chang, Anthony and Salem, Fadi and Kattan, Michael W and Schold, Jesse D and Connolly, Patricia and Rose, Angela and Doshi, Nehal and Gallon, Lorenzo and Donovan, Michael J},
title = {A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection},
journal = {Kidney360},
year = {2026},
volume = {7},
number = {8},
pages = {1792--1806},
doi = {10.34067/kid.0000001208}
}
EUVIMED